Nuclear magnetic resonance in oncology

Area of Science:

• Oncology
• Medical Imaging
• Biophysics

Background:

• Early research explored nuclear magnetic resonance (NMR) for cancer diagnosis based on tissue relaxation times (T1 and T2).
• Initial findings by Damadian were controversial and lacked widespread acceptance due to reproducibility issues and the need for in vitro analysis.
• The development of NMR imaging by Lauterbur significantly advanced the potential of NMR in oncology.

Purpose of the Study:

• To review the historical development and evolving role of NMR techniques in cancer diagnosis and evaluation.
• To highlight the transition from in vitro relaxation time measurements to in vivo NMR imaging.
• To discuss the future potential of in vivo NMR spectroscopy in clinical and experimental oncology.

Main Methods:

• Review of historical research on NMR relaxation times (T1 and T2) for differentiating tissues.
• Examination of the impact of NMR imaging technology for spatially encoded signal acquisition.
• Discussion of in vivo NMR spectroscopy using nuclei like 31P.

Main Results:

• In vitro NMR measurements of T1 and T2 times for cancer diagnosis faced significant challenges and controversy.
• NMR imaging enables non-invasive measurement of lesion T1 and T2 times, overcoming the need for biopsy.
• Initial in vivo proton relaxation time measurements for tissue characterization yielded disappointing results.

Conclusions:

• NMR imaging offers unique anatomical information for evaluating malignant disease without ionizing radiation.
• Despite initial setbacks in relaxation time measurements, NMR imaging is a powerful tool in oncology.
• In vivo NMR spectroscopy holds potential to further advance clinical and experimental oncology.